Abstract:The current adjuvant therapy for breast cancer is in a continous progress; standard therapeutic strategies include the use of chemotherapy, molecular targeted drugs and hormonal agents, according to well-established prognostic and predictive factors. Among the hormonal drugs, for a long period tamoxifen has been the gold standard of adjuvant therapy in postmenopausal women with hormone receptor-positive (HR+) early breast cancer. In the last years an expanding use of aromatase inhibitors occurred in this subset of patients, because the third-generation class of these agents (anastrozole, letrozole and exemestane) showed to be more effective and safe than tamoxifen and are now recommended as the preferred hormonal approach to postmenopausal hormone-sensitive patients, according to national and international guidelines. Treatment choices with these agents include the use of an aromatase inhibitor as an upfront strategy for 5 years, as a sequential approach after 2-3 years of tamoxifen, or as an extended use after the classical 5 years of tamoxifen. The improved efficacy of aromatase inhibitors over tamoxifen has been largely demonstrated in terms of better disease-free survival, reductions in the occurrence of early distant metastasis as well as improvement of overall survival. Moreover, according to the optimal duration of therapy, presently it is not known whether aromatase inhibitor therapy, as tamoxifen, should be limited to 5 years. In terms of safety profile, the side effects of aromatase inhibitors, as compared with selective estrogen receptor modulators, are different, reflecting the specific mechanism of action of these drugs. There is strong evidence that aromatase inhibitors are well tolerated, with a lower incidence of gynecological symptoms (vaginal bleeding, discharge and endometrial neoplasia), venous thromboembolic events and hot flushes than tamoxifen. On the other hand, the use of aromatase inhibitors has been associated with loss of bone density, arthralgia, myalgia, and a negative effect on lipid metabolism and cardiovascular risk. More extensive and mature studies are necessary to well establish the safety of aromatase inhibitors when given to patients with breast cancer for a long time.

Prevention of aromatase inhibitor–induced bone loss with anti-resorptive therapy in post-menopausal women with early-stage breast cancer

Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper

Incidence Of Menopausal Symptoms In Postmenopausal Breast Cancer Patients Treated With Aromatase Inhibitors

[A prospective study of bone loss in early stage postmenopausal breast cancer treated with aromatase inhibitors]

Adjuvant endocrine therapy effects on bone mineral density and microstructure in women with breast cancer

Aromatase inhibitor-induced bone loss osteosarcopenia in older patients with breast cancer: effects of the RANK/RANKL system's inhibitor denosumab vs. bisphosphonates

Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy: a 5-year follow-up

Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved

Early Denosumab for the prevention of osteoporotic fractures in breast cancer women undergoing aromatase inhibitors: A case-control retrospective study

Osteoporosis after adjuvant treatment for early-stage breast cancer

Effect of anastrozole on hormone levels in postmenopausal women with early breast cancer

Bone mineral density fall during aromatase inhibitor treatment may predict lower breast cancer recurrence

Molecular and clinical effects of aromatase inhibitor therapy on skeletal muscle function in early-stage breast cancer

Hormone therapy and osteoporosis in breast cancer survivors: assessment of risk and adherence to screening recommendations

Unveiling the Link Between Breast Cancer Treatment and Osteoporosis: Implications for Anticancer Therapy and Bone Health

Current role and safety profile of aromatase inhibitors in early breast cancer

Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo

Cancer Treatment-Induced Bone Loss (CTIBL): State of the Art and Proper Management in Breast Cancer Patients on Endocrine Therapy

Clinical Study of Aromatase Inhibitors in Advanced Breast Cancer

Anti-osteoporosis drugs and reduction of mortality in cancer patients

Prevention and Co-Management of Breast Cancer-Related Osteoporosis Using Resveratrol